Exercise program aims to boost muscle strength in kids with cystic fibrosis
NCT ID NCT06322446
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a home-based strength exercise program can improve muscle health in 48 children and teens with cystic fibrosis who are taking new CFTR modulator drugs. Participants are split into an exercise group and a control group. Researchers will measure muscle strength, lung function, and fitness to see if exercise helps manage side effects of the medication.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 48 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2024
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
6 to 20 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * patients diagnosed with CF. * patients between 6-20 years of age. * patients receiving treatment with new CFTR protein modulating medication * reading, acceptance and signing of the informed consent form. Exclusion Criteria: * CF patients with symptoms of pulmonary exacerbation during the last four weeks. * with a diagnosis of other cardiorespiratory lung diseases progressing to a symptom of persistent respiratory dysfunction. * CF patients with musculoskeletal alterations that influence assessments. * CF patient who is pregnant during the time of the study * CF patient with cognitive impairment; * CF patient with incomplete dosing of modulator therapy;
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cystic fibrosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Facultad de Ciencias de la Actividad Física y Deporte - INEF UPM
Madrid, Madrid, 28040, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Device-Preserved donor lungs boost transplant success?
- Can a simple questionnaire reveal why some cystic fibrosis patients skip physiotherapy?
- Cystic fibrosis diabetes: do gut hormones and genes hold the key?
- Can a special lung scan catch cystic fibrosis damage earlier than standard tests?
- Can a pill replace the liquid? testing a new form of cystic fibrosis drug
- Triple therapy under the microscope: does it transform cystic fibrosis care?